Specialized pharmaceutical manufacturer Jeron Selvain announced on the 10th that it successfully concluded the '2025 PDRN Symposium' held at Baekyang Nuri, Yonsei University.
The PDRN symposium was attended by over 500 domestic and international specialists who shared and discussed in-depth insights on the excellence of polydeoxyribonucleotide (PDRN) and its clinical application cases in the field of dental treatment.
The speakers included renowned domestic experts such as Professor Koo Ki-tae from Seoul National University Dental Hospital, Professor Kwon Yong-dae from Kyung Hee University Dental Hospital, Director Kim Sung-eon of Sejong Dental Clinic, Director Kim Yong-jin of Yesmir Dental Clinic, and Director Yoon Jong-il of Yeon Dental Clinic.
Each speaker presented on △ the basic mechanism of PDRN △ complication management using PDRN △ overcoming difficult cases with PDRN △ immunological approaches using PDRN in periodontal disease treatment △ clinical cases of PDRN applicable in private clinics △ accurate understanding and clinical application of PDRN, providing in-depth information based on clinical experience and research results.
Experts from various fields shared the latest clinical results and research on the efficacy and safety of PDRN, presenting diverse clinical studies and experimental outcomes. Discussions on actual clinical application cases and new treatment approaches followed, raising expectations for future research and industrialization possibilities.
Jeron Selvain’s ‘Selvain Injection’ utilizes the anti-inflammatory and pain-reducing mechanisms of PDRN to suppress inflammation-related factors and increase anti-inflammatory factors, simultaneously addressing inflammation and pain.
‘Selvain Injection’ is the only product based on the patented technology ‘Prism Technology (Prism-T)’ that manufactures nucleic acid fragments of uniform size without using chemicals, ensuring superior safety.
Through the symposium, Jeron Selvain explained and demonstrated the bone injection device ‘Soft Heel,’ scheduled for release in the second half of the year, attracting great interest from specialists.
Yoon Jong-il, Vice President of the PDRN Immune Regenerative Dentistry Research Association and Director of Yeon Dental Clinic, explained how immunity and dental clinical practice are related, stating, “Currently, interest in PDRN is increasing both domestically and internationally, confirming the innovative potential of PDRN.”
He continued, “The reason PDRN is clinically noteworthy is that compared to conventional antibiotic treatments, it controls inflammation and regenerates tissue with fewer side effects, effectively promoting patient healing. Active research is being conducted at the PDRN Immune Regenerative Dentistry Research Association,” he emphasized.
Kim Deok-gyu, CEO of Jeron Selvain, said, “As a physician treating patients, I began developing PDRN 10 years ago. At that time, the original developer of PDRN, Italy’s Mastelli, led the market, but now Jeron Selvain has succeeded in producing high-purity PDRN using a low-temperature extraction method without chemicals, unlike the conventional manufacturing method that uses high heat and harmful chemicals, gaining attention in the market.”
He added, “In clinical trials, Selvain Injection improved issues such as hyperlipidemia, allergic rhinitis, environmental dermatitis, and abnormal liver function. It also showed effectiveness in dental treatments as well as in disc treatment and postoperative recovery. Selvain Injection is the first PDRN created by clinicians and is excellent in regenerating nerve cells. When hospitals develop their own programs using Selvain Injection and apply them to patients, it is expected to yield excellent results, increasing satisfaction for both patients and hospitals.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
